Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Corcept Therapeutics Incorporated - Common Stock (NQ:CORT)

38.13 +3.34 (+9.58%)
Streaming Delayed Price Updated: 10:04 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Corcept Therapeutics Incorporated - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Nasdaq, S&P 500 Futures Point To Strong New-Year Open On Wall Street: Why TSLA, BIDU, SLV, STLA Are On Traders' Radar Today ↗
Via Stocktwits
Topics Stocks
News headline image
Stocks making big moves yesterday: FuelCell Energy, Corcept, and PacBio
Check out the companies making headlines yesterday: 
Via StockStory
News headline image
Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations
Via TheNewswire.com
News headline image
Kaplan Fox Announces an Investigation Into Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Why Is CORT Stock Falling Today? ↗
Via Stocktwits
News headline image
Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗
One of the company's key drugs won't be challenged by a competing medication anytime soon. 
Via The Motley Fool
News headline image
Why Corcept Therapeutics Plummeted by 50% Today ↗
The final day of 2025 saw the company get a sharp "no" from a top regulator. 
Via The Motley Fool
News headline image
Why Corcept (CORT) Shares Are Falling Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 51.4% in the afternoon session after the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) rejecting... 
Via StockStory
Here are the top movers in Wednesday's session. ↗
Via Chartmill
News headline image
Kaplan Fox &amp; Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations
Via TheNewswire.com
News headline image
Kaplan Fox & Kilsheimer LLP is Investigating Corcept Therapeutics, Inc. (CORT) for Potential Securities Law Violations
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
Top movers analysis in the middle of the day on 2025-12-31: top gainers and losers in today's session. ↗
Via Chartmill
The market is filled with gapping stocks in Wednesday's session. ↗
Via Chartmill
News headline image
Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism
From Corcept Therapeutics Incorporated
Via Business Wire
News headline image
3 Cash-Producing Stocks with Questionable Fundamentals
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. 
Via StockStory
News headline image
Why Corcept (CORT) Stock Is Trading Lower Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 4.7% in the afternoon session after investor anxiety mounted ahead of a key U.S. Food and Drug Administration (FDA) decision for its... 
Via StockStory
Topics Artificial Intelligence
News headline image
Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings?
Corcept has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13.8% to $81.75 per share while the index has gained 13.9%. 
Via StockStory
Topics Stocks
News headline image
Why Corcept (CORT) Stock Is Down Today
Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 9.2% in the afternoon session after investment bank UBS initiated coverage of the company with a Neutral rating. 
Via StockStory
Topics Artificial Intelligence Economy Supply Chain
News headline image
Corcept (CORT) Q3 2025 Earnings Call Transcript ↗
Corcept (CORT) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings Intellectual Property
News headline image
Corcept Therapeutics Inc (NASDAQ:CORT) Presents a Strong Growth and Technical Breakout Case ↗
Corcept Therapeutics (CORT) combines strong fundamentals, including robust revenue growth and a healthy balance sheet, with a positive technical breakout setup. 
Via Chartmill
News headline image
Penumbra, Corcept, Elanco, ResMed, and LeMaitre Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. 
Via StockStory
Topics Economy
News headline image
CORCEPT THERAPEUTICS INC (NASDAQ:CORT): A Case Study in Affordable Growth Investing ↗
Discover Corcept Therapeutics (CORT), a debt-free pharma stock with strong growth forecasts, solid profitability, and a reasonable valuation for balanced investing. 
Via Chartmill
News headline image
1 Growth Stock with Explosive Upside and 2 We Brush Off
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market value, a lesson ingrained in investors who... 
Via StockStory
News headline image
Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT)
Looking back on branded pharmaceuticals stocks’ Q3 earnings, we examine this quarter’s best and worst performers, including Corcept (NASDAQ:CORT) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
News headline image
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
The 5 Most Interesting Analyst Questions From Corcept’s Q3 Earnings Call
Corcept Therapeutics’ third quarter results drew a negative market reaction as the company’s revenue missed Wall Street expectations, despite robust year-on-year growth. Management highlighted... 
Via StockStory
Topics Earnings
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
Peering Into Corcept Therapeutics Inc's Recent Short Interest ↗
 
Via Benzinga
News headline image
CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook
Biopharma company Corcept Therapeutics (NASDAQ:CORT) missed Wall Street’s revenue expectations in Q3 CY2025, but sales rose 13.7% year on year to $207.6 million. The company’s full-year revenue... 
Via StockStory
News headline image
Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings
Biopharma company Corcept Therapeutics (NASDAQ:CORT) fell short of the markets revenue expectations in Q3 CY2025, but sales rose 13.7% year on year to $207.6 million. The company’s full-year revenue... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
12 13 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.